Alex C. Sapir
Chief Executive Officer
Alex C. Sapir joined ReViral in June 2019 as Chief Executive Officer. Prior to joining ReViral, Alex was the President and Chief Executive Officer at Dova Pharmaceuticals, Research Triangle Park, NC, USA from 2016 through 2018. During Alex’s tenure, Dova Pharmaceuticals evolved from a small private company to a 150-person fully-integrated publicly-traded biotech company (NASDAQ: DOVA) with an approved and marketed product, Doptelet® (avatrombopag), for the treatment of thrombocytopenia (i.e., low platelet counts).
Prior to becoming CEO at Dova Pharmaceuticals, Alex spent 10 years as Executive Vice President for United Therapeutics Corporation, a biotechnology company focused on pulmonary arterial hypertension and pediatric oncology. During his 10-year tenure at United Therapeutics, Alex was responsible for commercial activity, seeing the company grow from a one product company generating $80MM in revenues to a five-product company generating $1.6B annually.
Prior to his time at United Therapeutics Corporation, Alex was a consultant with ZS Associates, a consulting firm focused on strategy consulting for the pharmaceutical and biotech industry. Alex began his career at GlaxoSmithKline where he spent seven years in various commercial roles in the US and Europe.
Alex is a routine guest lecturer on the topic of pharmaceutical strategy at Duke University’s Fuqua School of Business. He holds a B.A. in Economics from Franklin and Marshall College and an M.B.A. from Harvard Business School.